Table 5 Effect of various factors like diabetes, ACS, EF, reason for stopping ticagrelor, time of stopping ticagrelor, and nature of new drug added instead of ticagrelor on our primary outcome
Primary outcome happened, N-17 | Primary outcome did not happen, N-292 | p value | |||
|---|---|---|---|---|---|
n | n% | n | n% | ||
Diabetes | 7 | 41.2 | 130 | 44.5 | 0.79 |
Acute coronary syndrome group | |||||
USA | 7 | 41.2 | 118 | 40.4 | 0.99 |
NSTEMI | 2 | 11.8 | 35 | 12.0 | |
STEMI | 8 | 47.1 | 139 | 47.6 | |
Ejection fraction | |||||
EF ≤ 30% | 0 | 0.0 | 8 | 2.7 | 0.8 |
EF ≥ 55% | 11 | 64.75 | 170 | 58.2 | |
EF-30–45% | 3 | 17.6 | 55 | 18.8 | |
EF-45–55% | 3 | 17.6 | 59 | 20.2 | |
Culprit vessel | |||||
Left anterior descending artery (LAD) | 7 | 41.2 | 160 | 54.8 | 0.32 |
Circumflex (LCX) | 2 | 11.85 | 49 | 16.8 | |
Right coronary artery (RCA) | 8 | 47.1 | 78 | 26.7 | |
Left main or triple vessel disease | 0 | 0.0 | 5 | 1.7 | |
Reason for stopping | 0.70 | ||||
Ticagrelor - not stooped | 6 | 35.6 | 67 | 22.9 | |
Ticagrelor stopped - physician-based decision | 1 | 5.9 | 1 | 14.7 | |
Ticagrelor stopped - cost | 10 | 58.8 | 178 | 61.0 | |
Ticagrelor stopped - non-availability of drug | 0 | 0.0 | 3 | 1.0 | |
Ticagrelor stopped - side effects | 0 | 0.0 | 1 | 0.3 | |
Nature of drug that was used during switch-over from ticagrelor | |||||
Ticagrelor continued | 6 | 35.3 | 67 | 22.9 | 0.45 |
Clopidogrel | 11 | 64.7 | 219 | 75.0 | |
Prasugrel | 0 | 0.0 | 6 | 2.1 | |
Timing of ticagrelor stopped and event | |||||
Not stopped | 6 | 35.3 | 66 | 22.6 | |
Stopped < 1 month | 2 | 11.8 | 13 | 4.5 | 0.44 |
Stopped 1–3 months | 1 | 5.9 | 31 | 10.6 | |
Stopped 3–6 months | 2 | 11.8 | 29 | 9.9 | |
Stopped 6–12 months | 3 | 17.6 | 49 | 16.8 | |
Stopped > 12 months | 3 | 17.6 | 104 | 35.6 | |